复方血栓通胶囊联合羟苯磺酸钙胶囊治疗非增殖期糖尿病视网膜病变临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R587.2

基金项目:


Clinical Study on Compound Xueshuantong Capsules Combined with Calcium Dobesi⁃ late Capsules for Non-proliferative Diabetic Retinopathy
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察复方血栓通胶囊联合羟苯磺酸钙胶囊治疗非增殖期糖尿病视网膜病变(DR) 气阴两虚 夹瘀证的临床疗效。方法:选取120例非增殖期DR气阴两虚夹瘀证患者,按照随机数字表法分为观察组和对 照组各60例。对照组采用羟苯磺酸钙胶囊治疗,观察组给予复方血栓通胶囊联合羟苯磺酸钙胶囊治疗。2组 均治疗3个月,随访1周。比较2组视力、视网膜神经纤维(RNFL) 厚度及黄斑厚度,记录不良反应。结果: 治疗1个月、3个月,观察组视力均较治疗前提高,且均高于同期对照组(P<0.05)。治疗1个月,对照组视力 与治疗前比较,差异无统计学意义(P>0.05)。治疗3个月,对照组视力较治疗前提高(P<0.05)。治疗3个月, 2组视乳头颞侧、上方、鼻侧、下方RNFL厚度均较治疗前增大(P<0.05),观察组视乳头颞侧、上方、鼻 侧、下方RNFL 厚度均大于对照组(P<0.05)。治疗1 个月、3 个月,2 组黄斑厚度均较治疗前缩小(P< 0.05),观察组黄斑厚度均小于同期对照组(P<0.05)。治疗期间及随访1周,对照组不良反应发生率6.67%, 观察组不良反应发生率5.00%,2组比较,差异无统计学意义(P>0.05)。结论:复方血栓通胶囊联合羟苯磺 酸钙胶囊治疗非增殖期DR气阴两虚夹瘀证安全有效,可增加RNFL厚度,缩小黄斑厚度,有效改善视力。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Compound Xueshuantong Capsules combined with Calcium Dobesilate Capsules for non-proliferative diabetic retinopathy (DR) with the syndrome of dual deficiency of qi and yin with blood stasis. Methods:A total of 120 cases of patients with non-proliferative DR with the syndrome of dual deficiency of qi and yin with blood stasis were selected and divided into the observation group and the control group according to the random number table method,with 60 cases in each group. The control group was treated with Calcium Dobesilate Capsules,and the observation group was treated with Compound Xueshuantong Capsules combined with Calcium Dobesilate Capsules. Both groups were treated for 3 months and followed up for 1 week. Visual acuity, retinal nerve fibers (RNFL) thickness and macular retinal thickness were compared between the two groups, and adverse reactions were recorded. Results: After 1 month and 3 months of treatment, the visual acuity in the observation group were improved when compared with those before treatment, and were higher than those in the control group at the same period (P<0.05). There was no significant difference in visual acuity before treatment and after 1 month of treatment in the control group (P>0.05). After 3 months of treatment,the visual acuity in the control group was improved when compared with that before treatment (P<0.05). The RNFL thickness of the temporal quadrant, superior quadrant, nasal quadrant, and inferior quadrant of optic disc in the two groups were increased when compared with those before treatment (P<0.05),and the RNFL in the observation group were thicker than those in the control group (P<0.05). After 1 month and 3 months of treatment,the macular retinal thickness in the two groups were reduced when compared with those before treatment (P<0.05), and the macular thickness in the observation group were lower than those in the control group at the same period (P<0.05). During treatment and after follow-up for 1 week, the incidence of adverse reactions was 6.67% in the control group and 5.00% in the observation group, there was no significant difference between the two groups (P>0.05). Conclusion: Compound Xueshuantong Capsules combined with Calcium Dobesilate Capsules is safe and effective in treating nonproliferative DR with the syndrome of dual deficiency of qi and yin with blood stasis. It can increase RNFL thickness,reduce macular retinal thickness,and effectively improve visual acuity.

    参考文献
    相似文献
    引证文献
引用本文

周秋菊,李俊,吴伯乐.复方血栓通胶囊联合羟苯磺酸钙胶囊治疗非增殖期糖尿病视网膜病变临床研究[J].新中医,2023,55(22):111-115

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2023-11-28
  • 出版日期:
文章二维码